1. Home
  2. RXRX vs MLYS Comparison

RXRX vs MLYS Comparison

Compare RXRX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.47

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.82

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
MLYS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
RXRX
MLYS
Price
$3.47
$27.82
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$7.50
$47.33
AVG Volume (30 Days)
21.9M
1.1M
Earning Date
02-27-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,689,000.00
N/A
Revenue This Year
$6.74
N/A
Revenue Next Year
$34.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.45
$8.24
52 Week High
$12.36
$47.65

Technical Indicators

Market Signals
Indicator
RXRX
MLYS
Relative Strength Index (RSI) 33.33 34.24
Support Level $3.54 $28.17
Resistance Level $4.09 $32.21
Average True Range (ATR) 0.26 1.61
MACD -0.07 -0.16
Stochastic Oscillator 3.10 4.29

Price Performance

Historical Comparison
RXRX
MLYS

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: